

Subject Index

(Numbers cited are abstract numbers)

- A**
A(E)BVD regimens 402
Abbreviated chemotherapy 011
Abdomen 537
Ablative chemotherapy 186
ABMT *see* Autologous bone marrow transplantation
ABPC *see* Autologous blood progenitor cell
Absolute neutrophil counts 664
ABV 170
ABVD (*see also* Adriamycin, Bleomycin, Vinblastine, DTIC) 170, 400, 406, 410, 416, 571
ABVD-MP regimen 442
Accessory factor-1 121
Acitretin 232
Active idiotypic vaccination 062
Acute B-cell leukaemia 325
Acute lymphoblastic leukaemia 437
Acute toxicity 180, 193
ACVB *see also* Adriamycin, Cyclophosphamide, Vindesine, Bleomycin 207
Adhesion molecules 236, 487
Adjuvant bacillus Calmette-Guérin therapy 555
Adjuvant combination radiotherapy 68
Adjuvant radiotherapy 651
Adolescence 095
Adoptive immunotherapy 155
Adrenoreceptor 676
Adriamycin 202, 285, 586
Adult lymphoblastic lymphoma 250
Adult T-cell leukaemia-lymphoma 697
Advanced follicular non-Hodgkin's lymphoma 549, 642
Advanced Hodgkin's disease 065, 160, 180, 211, 412, 427
Advanced large cell lymphomas 055, 198
Advanced low grade non-Hodgkin's lymphoma 540
Advanced lymphomas 654
Advanced multiple myeloma 701
Advanced non-Hodgkin's lymphoma-B 359
Advanced non-Hodgkin's lymphoma 558
Advanced stage indolent lymphomas 192
Advanced stage diffuse large cell lymphoma 200
Age 213
Aggressive chemotherapy 665
Aggressive clinical variant 339
Aggressive lymphoma 056, 185
Aggressive NK cell leukaemia 344
Aggressive NK non-Hodgkin's lymphoma 296
Aggressive nodal lymphoma 468
Aggressive non-Hodgkin's lymphoma 204, 208, 564, 569, 574, 580, 583, 586, 639, 643, 657, 658
AgNORs 331
AIDS-related lymphomas 049, 050
AK-2123 285
ALC *see* Anaplastic large cell lymphoma
ALCL-Hodgkin's like 571
All-trans-retinoic acid 312
Allogeneic blood stem cell transplantation 622, 623, 624
Allogeneic bone marrow transplantation 251
ALPS *see* Autoimmune lymphoproliferative syndrome
Alternative therapy 421
America (American) 003
Anaemia 320
Anaplastic large cell lymphoma (ALCL) 016, 041, 089, 122, 123, 124, 333, 557
Ante-mortem diagnosis 451
Anthracycline 405, 503, 554, 602
Anti-ALK antibody 016
Anti-CD20 monoclonal antibody 195
Anti-CD30/CD16 bispecific antibody (Bi-Mab) 179
Anti-CD40 antibodies 137
Anti-follicular lymphoma 061
Anti-tumour activity 233
Anti-tumour response 062
Antigen receptor gene rearrangements 304
Antigen selection 526, 527
Antineoplastic chemotherapy 307
Antiretroviral therapy 616
Antracyclines 579
Apoptosis 087, 154, 353, 381
ARA-C therapy 452
ASCT *see* Autologous stem cell transplantation
ASHPA 589
Asymptomatic patients 175
Austrian Multicenter Trial 238
Autogeneic marrow transplant 060
Autografting 642
Autoimmune lymphoproliferative syndrome (ALPS) 302
Autologous bone marrow transplantation (ABMT) 079, 243, 644, 647, 657, 658, 661, 663,
Autologous circulating progenitor cell transplant 637
Autologous PBPC transplantation 631, 654, 655
Autologous stem cell transplantation (ASCT) 053, 056, 057, 058, 248, 638, 646, 648, 660, 671
Autologous transplantation 634
Autologous blood progenitor cell transplantation 649
Autotransplantation 630
AZT *see* Zidovudine
- B**
B-ALL 015
B-cell 031
B-cell chronic lymphocytic leukaemia 688, 689
B-cell large cell lymphoma 092
B-cell lymphomas 106, 509
B-cell non-Hodgkin's lymphoma 048, 126, 153, 309, 525
B-cl gene mutations 046, 047
B-CLL 319
B-lymphocytes 380
B-non-Hodgkin's lymphoma BFM-90 protocol 362
B-non-Hodgkin's lymphoma 362
B7 immunotoxins 445
Baboons 281

- Bcl-1 translocation 496
 Bcl-1/cyclin D1 063
 Bcl-2 162
 Bcl-2 antisense therapy 100, 101
 Bcl-2 expression 085
 Bcl-2 gene 023, 127, 129
 Bcl-2/IgH 324
 Bcl-2/IgH rearrangements 521
 Bcl-2/IgH translocation 305
 Bcl-2 MBR arrangements 085
 Bcl-2 mRNA 447
 Bcl-2 protein 084, 447, 487
 Bcl-2 rearrangement 051, 520
 Bcl-2 translocation (t14;18) 108
 Bcl-6 127
 Bcl-6 gene 298
 Bcl-6 protein 046
 Bcl-6 rearrangement 051
 Bcl-6 regulatory regions 049
 BEAM scheme, the 645
 BECOP regimen 564
 Bendamustine 544
 Bi-Mab *see* Bispecific antibody
 Bilateral bone marrow biopsy 336
 Bleomycin 199, 575, 609, 616
 Blood and marrow transplantation 635
 BNL1 patients 174
 BNLI study 085
 BNLI trials 055
 Body-cavity-based lymphomas 143
 Bone marrow 252, 280, 305, 522, 626, 643
 Bone marrow-stem cells 639
 Bone marrow leukocytes 532
 Bone marrow transplantation 250
 Bone 259
 Brief chemotherapy 067
 British National Lymphoma Investigation 404
 Bulky mediastinal 169
 Bulky tumour 409
 Burkitt's lymphoma 014, 015, 092, 098, 148, 215, 354, 363, 370, 582, 612, 613
 Burkitt-like lymphoma 582
 Busulfan 655, 659, 674
- C**
 C.B-17 *SCID/SCID* mice 155
 C-myc 014
 C-reactive protein 495
 C5R protocol 453
 CA-125 321
 CAMPATH-1H® antibody 556
 CAP 074
 Carbamazepine 512
 Cationic lipid delivery 014
 CB/CC diffuse 088
 CCNU 423
 CCP regimen 551
 CD-40 activation 139, 140
 CD-5 positive diffuse large B-cell lymphoma 119
 CD11a/CD18 236
 CD23 receptor 319
 CD23 serum level 687, 688
 CD23 525
 CD25 receptor 319
 CD28 292
 CD3 292
 CD30 ligands 020, 149
 CD30+ primary cutaneous lymphoma 483
 CD34+ cell selection 242
 CD34+ blood cell selection 642
 CD34+ progenitor cells 052
 CD34-immunoaffinity column 631
 CD40 ligand 137
 CD44 157
 CD44 236, 255
 CD44 S 384
 CD5(+) immunocytoma 316
 CD54 236 *see also* ICAM-1
 CD69 525
 CD72 antigen 140
 CD83 159
 2-CDA *see* 2-Chlorodeoxyadenosine
 CDA-related lymphopenia 105
 CDKN2 (p16^{INK4A}) tumour suppressor gene 133
 Cell lineage 300
 Cell lines 157, 293
 Cell proliferation 022
 Cell growth 322
 Central nervous disease 197
 Centroblastic lymphoma 502
 Centrocytic lymphoma 211
 CEOP 575
 CEOP/CNOP alternating therapy 579
 CEOP regimen 539
 CEVD salvage regimen 430
 CEVOP-B regimen 599
 Challenge 440
 Chemoradiotherapy 373
 Chemotherapy 011, 037, 062, 198, 358, 403, 463, 480, 536, 538, 569, 588, 645, 653, 699
 Chemotherapy-resistant diffuse non-Hodgkin lymphoma 054
 Childhood 013, 016, 018, 091, 092, 095, 348, 352, 353, 355, 356
 Childhood Hodgkin's disease 258, 364, 365, 366, 367, 368, 369, 372
 Childhood T-cell lymphoma 253
 Children 012, 256, 261, 486
 Children's Cancer Group 097
 Chimeric antiCD20 antibody 108, 194
 Chlorambucil 546
 2-Chlorodeoxyadenosine (2-CDA, cladribine) 073, 105, 237, 238, 239, 240, 241, 505, 507, 508, 509, 691, 692, 693
 CHOEP chemotherapy 210, 576
 CHOP 036, 055, 076, 077, 078, 209
 CHOP regimen 575, 580
 CHOP-Bleo therapy 543
 CHOPE 413
 Chromosomal abnormality 297

- Chromosomal translocation 294, 499
 Chromosome 12 682
 Chromosome 18 521
 Chronic lymphocytic leukaemia (CLL) 034, 053, 074, 110, 140, 234, 239, 678, 680, 684, 687, 688, 689, 694
 Chronic B lymphoid disorders 297
 CHVmP 199
 Cisplatinum 177
 Cladribine *see also* 2-Chlorodeoxyadenosine (2-CDA) 553, 554, 696, 697
 Classification 004, 005, 042
 Clinical analysis 252
 Clinical aspects 040
 Clinical behaviour 006
 Clinical characteristics 119
 Clinical correlations 063
 Clinical multicentre trial 135
 Clinical stage 066, 236, 256, 406
 Clinical stage I-II Hodgkin's disease 166, 167
 Clinical study 005
 Clinical trials 514
 Clinico-histopathological study 475
 Clinico-pathological analysis 117, 120
 Clinico-pathological correlation 619
 Clinico-therapeutic implications 391
 Clinicopathology 357, 454, 457, 460, 508
 Clinicoprognostic entity 509, 510
 CLL *see* Chronic lymphocytic leukaemia
 Clonal access 335
 Clonal IgH-CDR3 rearrangement 499
 Clonal immunoglobulin heavy chain arrangement 126
 Clone 374
 Clone-specific primers 632
 Clone specific variable regions 130
 Cmyc oncogene 361
 CNS relapse 566
 Combination chemotherapy 173
 Combined modality treatment 069, 193, 398, 410
 Combined therapy 434, 538
 Comparative genomic hybridisation 131
 Competitive PCR 128
 Complete remission 079, 533
 Computerised classification 532
 Conservative management 542
 Consolidation 207
 Cooperative growth factors 314
 COPP 170, 410
 Cost-effectiveness 392
 CPP32 151
 CR1 644
 Cranial irradiation 099
 Croatia 366
 Cryopreservation 516
 Curative intent 080
 Cure 001
 Current classification system 683
 Cutaneous B-cell lymphomas 040, 229
 Cutaneous lymphocyte associated antigen 489
 Cutaneous lymphoma 042, 043, 044
 Cutaneous lymphoproliferations 124
 Cutaneous non-Hodgkin's lymphoma 486
 Cutaneous T-cell lymphomas 038, 145, 229, 491
 Cyclin-dependant kinase inhibitor P15 118
 Cyclophosphamide 074, 202, 206, 553, 583, 609, 640, 659
 Cysteine proteases 151
 Cytogenetic findings 326
 Cytokine chemotactic 145
 Cytokine transfer 313
 Cytokines 372, 491
 Cytokinesis 288
 Cytology 328
 Cytolytic T-lymphocyte 146
 Cytomorphology 348
 Cytoreductive chemotherapy 547
 Cytoreductive treatment 189
 Cytosine arabinoside 545
 Cytotoxic lymphocytes 450
 Cytotoxic T lymphocytes 155, 220
- D**
- D13S272 134
 D13S273 134
 Daunorubicin 601
 DCLSG-non-Hodgkin's lymphoma-94 Study 257
 Decision analysis model 478
 Dendritic cell 159
 Dermatologist's perspective 044
 Dexamethasone 546, 547, 551, 695, 701
 DHAP chemotherapy 541, 630
 dic(4;17)(p11;p11) 297
 Didemnin 594
 Differential display 293
 Diffuse aggressive lymphomas 203
 Diffuse centrocytic lymphomas 506
 Diffuse large B-cell lymphomas 083, 084, 127, 326, 327, 328
 Diffuse large cell non-Hodgkin's lymphoma 085, 561
 Diffuse large cell lymphoma 036, 335, 578
 Diffuse low grade non-Hodgkin's lymphoma 541
 Diphtheria toxin 233
 Discordant bone marrow 335
 Disease progression 176
 Disease phases 329
 Disease-free survival 097, 189
 Disseminated high grade non-Hodgkin's lymphoma 577
 Disseminated intermediate non-Hodgkin's lymphoma 577
 Disseminated large cell non-Hodgkin's lymphoma 097
 Disseminated non-lymphoblastic Non-Hodgkin's lymphoma 093
 DNA-hydrolysing autoantibodies 684
 Dose intensity 414
 Dose-escalating CHOP 204
 Double intensive therapy 191
 Doxorubicin 074, 168, 171, 261, 573
 DRASH syndrome 363
 Dutch Cutaneous Lymphoma Working Group, the 482
- E**
- Early ASCT 672, 673

Early-relapsed Hodgkin's disease 178
 Early stage Hodgkin's disease 067, 068, 181a
 Eastern Cooperative Oncology Group 594
 EBMT/UKLG randomised trial 660
 EBV-induced lymphomas 060
 EBV infection 161
 EBV protocol 369
 EBV serology 382
 EBVP chemotherapy 616
 EFS 098
 Egypt 267, 557
 Elderly lymphoma patients 080, 208, 210, 395, 396, 397, 399, 604, 606, 607, 609, 610, 614
 Endocrine disorders 373
 Endonuclease 144
 Endoscopic ultrasound 228
 Endoscopy 479
 End-stage lymphoma 622
 England 389
 Engraftment 628
 Enteropathy associated T-cell lymphomas 220
 EORTC classification 230
 EORTC/GPMC trial 070
 Eosinophils 020
 EpiADM 599
 Epidemiology 262, 265
 Epidermotropism 145
 Epirubicin 415, 583, 596, 609, 616, 641
 Epstein-Barr virus 018, 022, 024, 030, 143, 155, 162, 254, 267, 294, 450, 681
 ESHAP protocol 595
 Essential mixed cryoglobulinaemia 700
 Etoposide 168, 171, 177, 202, 206, 415, 641
 Europe (European) 003, 027
 European survey 072
 EVA chemotherapy 168
 Extended-field radiotherapy 411
 Extramedullary plasmacytoma 702
 Extranodal lesions 115

F

F.I.S.H. 123
 F-MACHOP regimen 647
 Failure-free survival 192
 FAS function 301, 302
 FAS ligand 303
 FDG PET scanning 114
 Femoral marrow 113
 Field radiotherapy 169, 371
 Filgrastim (rG-CSF) 173, 252, 583, 667, 668
 First-line chemotherapy 651
 First-line therapy 531, 694
 First-line treatment 405
 First relapse 426, 586, 694
 First remission 248
 Florence, Italy 440, 441, 481
 FluDAP regimen, the 633
 Fludarabine 74, 110, 550, 551, 552, 695, 700

Fluorescence *in situ* hybridisation 132, 682
 Follicle center lymphoma 447
 Follicular cutaneous T-cell lymphoma 341
 Follicular lymphomas 032, 051, 075, 129, 131, 132, 139, 191, 194, 244, 246, 324, 526, 531, 536
 Follicular non-Hodgkin's lymphomas 073, 128, 242, 519, 541, 548
 French Pediatric Oncology Society 096

G

G-CSF (Granulocyte colony-stimulating factor) 312, 584, 585, 610, 611, 616, 618, 665 *see also* Filgrastim, Neupogen®
 G-CSF therapy 249, 639
 G1 growth arrest 353
 GA-67 scintigraphy 272, 273, 274, 275
 Gallium-67 scan 111
 Gastric 274
 Gastric B-cell MALT lymphomas 222
 Gastric large-cell lymphoma 476
 Gastric lymphoma 029, 227
 Gastric MALT lymphoma 007, 009, 468, 479
 Gastric non-Hodgkin's lymphoma 469
 Gastrointestinal lymphomas 475
 GELA study 080, 163, 207, 412, 550
 GELF86 trial, the 510
 Gene therapy 291
 Genetic abnormalities 131
 Genetic lesions 017, 323
 Genomic DNA amplification 089
 Genotype 347
 Genotypic analysis 289, 505
 German Hodgkin Study Group 164, 414
 German non-Hodgkin's lymphoma-Consensus Trial Group, the 201
 Germinal centre 298
 GISL controlled study 511
 GISL registry, the 184
 Global health status 513
 Glomerulonephritis 621
 Glycosaminoglycans 689
 GM-CSF 312, 584, 665
 GOELAMS protocol 609, 646
 GOELAMS trials 448, 567
 Granulocyte colony-stimulating factor *see* G-CSF
 Group E patients 511
 Gruppo Veneto Linfomi, the 605

H

H5 EORTC trials 166
 H90-MA protocol 409
 Haematological disorders 138
 Haematological malignancies 685
 Haematological neoplasias 431
 Haematolymphopoietic malignancies 264
 Haematopoiesis 637
 Haemopoietic cell grafts 242
 Haemopoietic growth factors 666
 Haemopoietic support 674
 Hairy cell leukaemia 241, 692, 696
 Haptoglobin 318

- HBV carriers 150
 Head and neck aggressive non-Hodgkin's lymphoma 449
Helicobacter pylori 224, 225, 226, 472, 476, 479
 Hepatitis C 308, 311, 517, 518, 690
 Heterozygosity 284
 High dose chemotherapy 037, 252, 531, 668, 669
 High dose DHCAT regimen 652
 High dose radiochemotherapy 654
 High dose sequential ablative chemotherapy 670
 High grade B-cell non-Hodgkin's lymphoma 086
 High grade gastric lymphoma 480
 High grade MALT lymphoma 224, 472
 High grade non-Hodgkin's lymphoma 135, 199, 201, 247, 558, 559, 560, 562, 563, 572, 585, 606, 607, 611, 614, 650, 652
 High malignant non-Hodgkin's lymphoma 548
 High risk diffuse large cell lymphoma 249
 High risk Hodgkin's disease 417
 High risk lymphoid malignancies 634
 High risk non-Hodgkin's lymphoma 589
 High risk small non-cleaved cell lymphoma 358
 Histiocytoses 343
 Histochemistry 315
 Histologic nodular pattern 190
 Histologically aggressive non-Hodgkin's lymphoma 608, 609
 Histopathology 164, 263
 HIV 276
 HIV infection 215, 307
 HIV positive CD30+ ALCL 334
 HIV related Hodgkin's disease 214
 HIV related non-Hodgkin's lymphoma 213, 615, 617
 HIV related systemic Non-Hodgkin's lymphoma 619
 HKB-1 cell line 289
 Hodgkin's disease 001, 011, 012, 013, 018, 019, 020, 161, 035, 057, 058, 111, 069, 151, 279
 Hodgkin's disease survivors 181
 Hodgkin-Reed Sternberg cells 160, 288, 291
 Homeobox B genes 283
 Hong Kong 029
 HTLV-1 315, 342
 Human myeloma cell lines 286
 Human non-Hodgkin's lymphoma 313
 Human pre-B cell lymphoma 676
 Hybrid regime 172
 Hypercalcaemia 620
 Hypothyroidism 442
- I**
- ICAM-1 (CD54) 152, 255
 Idarubicin 546, 578, 587
 Idiohepatic cholestasis 446
 IEV regimen 641
 Ifosfamide 177, 545, 587, 593, 596, 641
 IgH alterations 299
 IgH rearrangements 563
 IgL rearrangements 563
 IL-2 receptor 685
 IL-4 137
 IL-8 231
 Image-guided core needle biopsy 269
 IMEP 170
 Immune cytotoxic T-cells 060
 Immune status 528
 Immunocompetence 214
 Immunocytochemistry 469, 505
 Immunodeficient mice 158
 Immunoglobulin 632
 Immunoglobulin gene rearrangements 243
 Immunohaematology 235
 Immunohistopathology 376
 Immunological reconstitution 662
 Immunological sanctuaries 303
 Immunology 214
 Immunomagnetic beads 661
 Immunomodulatory therapy 090
 Immunophenotype 562
 Immunophenotypic analysis 141
 Immunophenotyping 523
 Immunostaining 350
 Immunosurveillance 149
 Immunotherapy 291
 Immunotoxins 107
 Improvement 033
In situ hybridisation 483, 496
 Incidence 026
 India 388
 Indolent 157
 Indolent lymphoma patients 552
 Induction chemotherapy 250
 Infradiaphragmatic Hodgkin's disease 408
 Intensified high-dose sequential chemotherapy 504
 Intensive sequential chemotherapy 636
 Interferon alpha 090, 189
 Interferon alpha-2a 493
 Interferon alpha-2b 190, 425, 492, 539
 Interferon study 075
 Interferons 232, 312, 491, 547, 699, 701
 Interleukin-1 352
 Interleukin-15 148
 Interleukin-2 105
 Interleukin-3 603
 Interleukin-3 665
 Interleukin-6 329
 Interleukins 312, 314, 529, 685, 686
 Intermediate differentiation lymphoma 506
 Intermediate grade non-Hodgkin's lymphoma 247, 558, 562, 563, 573, 606, 607, 652
 Intermediate resectable primary gastric lymphoma 478
 Intermediate stage Hodgkin's disease 411
 International index 033
 International Lymphoma Study Group 005
 International Prognostic Factors Project 065
 International Prognostic Index (IPI) 184, 185, 247, 468, 565
 Intestinal lymphoma 219
 Involved field radiation therapy 569
 Involved-field radiotherapy 180, 411, 473

- IPI *see* International Prognostic Index
 IPSID-related lymphoma 624
 Irradiation 406
 IS IP-10 145
 Isoenzyme 349
 Italian Multicenter Study 264
 Italian Non-Hodgkin's Lymphoma Cooperative Study Group 581
 Italian study 028
 IWF:A-D 108
- J**
 Japan 150
 Jerusalem, Israel 265, 419
- K**
 K-ras mutation 351
 Kaposi's sarcoma 025, 142, 143
 Kaposi's sarcoma-associated herpesvirus 025, 14, 143
 Ki-1 343
 Ki-1 positive ALCL 357
 Ki-1 positive lymphoma 557
 Ki-A10 antigen 377
 Ki67 antibody 306
 Kidney transplantation 363
- L**
 L-selectin 157
 LABO regimen 428
 Lactate dehydrogenase 349
 Lamins 290
 Large cell anaplastic lymphoma 094, 570
 Large cell lymphoma 360
 Late complications 438
 Late effect 181a
 Late pulmonary effects 434
 Late relapse 200
 Late toxicity 180
 LDH 187, 213
 LECAM-1 236
 Lenograstim 640
 Leukaemia 028, 107
 Leukaemic dissemination 186
 Limited field radiotherapy 066
 Liposome 602
 Literature review 621
 LMB 89 protocol 092, 093, 260
 LNH87 trial, the 510
 Localised extra-nodal aggressive non-Hodgkin's lymphoma 448
 Localised follicular non-Hodgkin's lymphoma
 Localised gastric non-Hodgkin's lymphoma 473, 477
 Localised nodal aggressive non-Hodgkin's lymphoma 567
 Localised unfavourable non-Hodgkin's lymphoma 076, 168, 398
 Long PCR 015
 Long-term follow-up 077
 Long-term Hodgkin's disease survivor 435
 Long-term toxicity 035
 Longtime outcome 346
 LOPP regimens 428
 Low dose chemotherapy 037
 Low grade B-non-Hodgkin's lymphoma 137
 Low grade gastric MALT lymphoma 226
 Low grade lymphoid malignancies 133
 Low grade lymphoma 109, 110, 251, 543
 Low grade malignant non-Hodgkin's lymphoma 544
 Low grade MALT lymphoma 224
 Low grade non-Hodgkin's lymphoma 237, 275, 317, 336, 532, 538, 542
 Low toxicity 415
 LP-HD *see* Lymphocyte-predominant Hodgkin's disease
 LVPP regimen 540
 Lymph nodes 156, 290
 Lymphoblastoid cell line 293
 Lymphocyte 447, 689
 Lymphocyte-depletion Hodgkin's disease 387
 Lymphocyte population 379
 Lymphocyte-predominant Hodgkin's disease (LP-HD) 021
 Lymphocytic lymphoma 506
 Lymphography 279
 Lymphoid irradiation 669
 Lymphoid malignancies 045, 623
 Lymphoid neoplasms 116
 Lymphoma (*see also* Malignant lymphoma) 002, 003, 007, 008, 010, 023,
 024, 026, 028, 107, 262, 272, 436
 Lymphomatoid papulosis 041, 089, 483
 Lymphoproliferative disorders 141, 231, 270, 662, 627
 Lymphoproliferative response 677
 Lymphotoxin 301
 Lysis 280
- M**
 M-BAIOD 593
 Macaque lymphoma 282
 MACOP-B therapy 077, 078, 200, 571
 Magnetic resonance imaging 113
 Malignancies 183
 Malignant lymphoma 025, 026, 063, 064, 087, 102, 113, 114, 150, 262, 283,
 318, 361, 370, 517, 524, 588, 604, 605, 675
 Malignant B-cell lymphomas 154
 Malignant lymphoproliferative diseases 235
 Malignant non-Hodgkin's lymphoma 078
 MALT histology 221
 MALT *see* Mucosa associated lymphoid tissue
 MAMA regimen 418
 MAMI protocol 592
 Mantle cell lymphomas 072, 117, 140, 211, 212, 494, 495, 497, 498, 499,
 500, 501, 502,
 504 Mantle field radiotherapy 271
 Mantle radiotherapy 439
 Marginal zone B-cell lymphoma 125, 339
 Masangioproliferative glomerulonephritis 340
 Match-controlled study 057
 Mature B-cell lymphoma/leukaemia 091
 Mature plasma cells 287
 mBACOD *see* Polichemotherapy
 Mediastinal disease 273
 Mediastinal radiotherapy 422
 Mediastinal tumour size 386

- Mediastinum 196
 Medical sequelae 181
 Mediterranean abdominal lymphoma 463
 Melphalan 674
 Meta-analysis 068, 075
 Metacronous small cell lung cancer 436
 Metastasis 157
 Methotrexate 617
 Methylglyoxalbisguanylhydrazone 280
 Methylthioadenosine phosphorylase (MTAP) 045
 MHC class I 375
 Mib1 antibody 306
 Mice 284
 MiCEP treatment 607
 MICMA protocol 591
 Minimal therapy 256
 Minor salivary gland 447
 Maintenance therapy 425
 Mitoxantrone 206, 423, 547, 551, 574, 615, 695
 MMAA regimen 418
 Molecular analysis 252
 Molecular biology 004, 008
 Molecular cytogenetic analysis 135
 Molecular genetic features 497
 Molecular lesions 327
 Monoclonal antibodies 046
 Monoclonal antibody therapy 556
 Monoclonal gammopathies 690
 Monoinstitutional study 215
 Mononuclear cells 160, 172
 MOPP 402
 MOPP/ABV hybrid 417, 419
 MOPP/ABVD hybrid 012, 420, 421, 422
 Morocco 364
 Morphological subtype 236
 Morphological transformation 129
 Mouse leukaemic cells 285
 MR imaging 277
 mRNA expression 147
 MSKCC prognostic model 412
 MTAP *see* Methylthioadenosine phosphorylase
 MTX therapy 452
 Mucinoses 341
 Mucosa associated lymphoid tissue (MALT) lymphoma 008, 223, 228, 471, 472
 Multidimensional Geriatric Assessment 513
 Multidrug resistance 378
 Multidrug resistance modulator 104
 Multiple myeloma 146, 699
 Multivariate analysis 317
 Murine 313
 Murine fibroblasts 137
 Muscle 462
 Mutation 048, 461
 MVP 404
 MVPP chemotherapy 371
 Mycosis fungoides 485, 492, 493
 Myeloablative high-dose therapy 245
 Myeloablative therapy 632, 634
 Myelodysplastic syndrome 473
- N**
- N-ras mutation 351
 Nasal lymphoma 450
 Nasal T/NK-cell lymphoma 120
 Natural killer cell lymphomas 347
 Neo-adjuvant chemotherapy 066
 Neoplasms 450, 683
 Neoplastic B cell 301
 Neoplastic B-cell development 031
 Neoplastic lymphoid tissues 046
 Neupogen® (Short G-CSF) 664
 Neutropaenia 664
 Neutrophil 585
 New drugs 102
 NHL *see* Non-Hodgkin's lymphoma
 Nitrogen-mustard derivative 544
 Nodular lymphocyte predominance Hodgkin's disease 163
 Nodular sclerosis 386
 Non-anthracycline chemotherapy 608
 Non-gastrointestinal lymphoma 223
 Non-gastrointestinal mucosa-associated lymphoid tissue lymphoma 010
 Non-haematopoietic malignancies 494
 Non-Hodgkin's lymphoma 062, 103, 147, 151, 183, 205, 307, 308, 311, 355, 584, 653, 686
 Non-Hodgkin's Lymphoma Co-operative Study Group 206
 Non-Hodgkin's lymphoma-15 protocol, the 203
 Non-Hodgkin's lymphoma-BFM 90 091
 Non-Hodgkin's lymphoma-CCL-like 553
 Non-Hodgkin's lymphoma-CSG, the 643
 Non-Hodgkin's malignant lymphoma 555
 Non-invasive diagnosis 276
 Non-MALT histology 221
 Noradrenaline 676
 Nordic Lymphoma Study Group 078
 NPM/ALK fusion transcripts 019
 Nuclear antigens 331
 Nucleolar organizer regions 306
- O**
- Ocular adnexal pseudolymphoma 461
 Oncogenesis 064
 Oncologist's perspective 043
- P**
- p* gene loss 136
 P-glycoprotein 378
 P-VABEC treatment 607
 p53 331
 p53 expression 530, 560, 676
 p53 gene 048
 p53 mutation 118
 p53 protein 084, 162
 p53 rearrangement 461
p80(npm-alk) fusion protein 383
 Paclitaxel (Taxol®) 103

- Paediatric Burkitt's lymphoma 259
 Paediatric lymphoma 349, 350
 Paediatric malignant lymphoma 255, 373
 Paediatric protocol 098
 Parma, Italy 054
 Parma trial, the 247
 Partial remission 070, 672
 Passive antibody protection 158
 Pathogenesis 029, 038, 127
 Pathogenic hypothesis 442
 Pathology 007, 040, 214
 PBMCculture 685
 PBPC *see* Peripheral blood progenitor cell
 PBPC mobilisation 640
 PBPC rescue 667
 PBPC transplantation 640, 659
 PBSC *see* Peripheral blood stem cells
 PBSC infusion 246, 662
 PBSC rescue 652
 PBSC support 651
 PBSC transplantation 212, 245, 656, 675
 PBSC therapy 550
 PCNA expression 331, 530, 560
 PCR analysis 109, 243, 305, 469, 523
 Pediatric Oncology Group Study 259
 Peripheral T-cell lymphoma (PTL) 082, 202
 Peripheral blood 381, 532
 Peripheral blood lymphocytes 149
 Peripheral blood progenitor cell (PBPC) 626
 Peripheral blood stem cell (PBSC) 632, 639
 Peripheral blood stem cell transplantation 625
 Peripheral stem cells 186
 Peripheral T cell lymphoma 095, 345
 Peripheral T-cell non-Hodgkin's lymphoma 356
 PET *see* Positron emission tomography
 PET-FDG subdiaphragmatic nodal assessment 279
 Pharmacokinetics 100, 693
 Phase I trial 101, 104, 165, 179, 697, 701
 Phase II trial 093, 104, 165, 179, 240, 413, 492, 587, 594, 597, 691, 694, 701
 Phase III trial 194, 201, 603
 Phenotype 347
 Phosphoprotein 298
 Phototherapy 492, 493
 Phytohaemagglutinin 677
 Pleomorphic large T-cell lymphomas 083
 PmitCEBO therapy 590
 POF LCP 88 trials 216
 POF81 protocol 409
 Polichemotherapy (mBACOD) 190
 Polish Pediatric Leukemia Lymphoma Study Group 260, 359, 360
 Polyamine synthesis 280
 Polychemotherapy 519, 542
 Polymerase chain reaction *see* PCR
 Polymorphism 527
 Poor prognosis 428, 595
 Poor prognosis Hodgkin's disease 424
 Poor prognosis lymphoma 636
 Poor prognosis non-Hodgkin's lymphoma 649
 Poor risk Hodgkin's disease 673
 Poor risk patients 565
 Positron emission tomography (PET) 112, 115, 278
 Post-therapeutic late gonadal dysfunction 516
 Post-transplant lymphoma 136
 Post-transplant lymphoproliferative disorders (PT-LPDs) 047, 090, 459
 Pre-autograft chemotherapy 633
 Precursor cells 345
 Predictive tool 321
 Prednimustine 547, 615
 Prednisolone 206
 Prednisone 074, 202, 553, 609, 616
 Pregnancy 416
 Prescription, progress 2
 Pretransplant status 673
 Pre-treatment intensity index 429
 Primary ALCL 337
 Primary breast lymphoma 460
 Primary cardiac lymphoma 451
 Primary central nervous system lymphoma 216, 452, 454
 Primary cerebral lymphoma 276
 Primary cerebral non-Hodgkin's cerebral lymphoma 453
 Primary chemotherapy 171, 176
 Primary cutaneous B-cell lymphoma 489
 Primary cutaneous large B-cell lymphomas 487, 488, 490
 Primary cutaneous lymphoma 230, 481, 482, 485
 Primary extra-gastric localisation 471
 Primary gastric non-Hodgkin's lymphoma 225, 474
 Primary gastrointestinal lymphoma 465, 466
 Primary gastrointestinal non-Hodgkin's lymphoma 467, 470
 Primary lymphoma 081
 Primary mediastinal Hodgkin's disease 407
 Primary mediastinal large B-cell lymphoma 565
 Primary non-Hodgkin's lymphoma 196
 Primary renal lymphoma 340
 Primed peripheral blood stem cells 252
 Primer amplification 130
 Priming therapy 630
 Primitive plasma cells 287
 Prior medical conditions 515
 Problems 443
 Progenitor cells 641
 Prognosis 030, 038, 176, 205
 Prognostic factors 166, 275, 317, 319, 320, 331, 393, 399, 500, 501, 559, 560, 561, 562, 564, 605, 606
 Prognostic index 065, 187, 394
 Prognostic marker 687
 Progressive lymphomas 299
 ProMACE regimen 502
 ProMACE-CytaBOM therapy 549, 618
 ProMACE-CytaBOM-like regimen 574
 ProMACE-MOPP therapy 473
 Prophylaxis 197, 566
 Prospective multicentre study 081
 Protein-10 491
 Protooncogenes 323
 PSC 833 104
 PT-LPDs *see* Post-transplantation lymphoproliferative disorders

PTL *see* Peripheral T-cell lymphoma
 Pulmonary Hodgkin's disease 438
 Pulmonary lymphoproliferative disorder 218
 Pulmonary sequelae 013
 Purged ABMT 650
 Purged autologous bone support 531
 Purged PBPC transplantation 628
 Purified blood-stem cells 638
 PUVA 232

Q

6q23-24 132
 Quality of life 181

R

Rabbit 282
 Radiation therapy 193
 Radiation-induced apoptosis 310
 Radiation-induced lymphomas 284AK-2123 285
 Radioimmunotherapy 106
 Radiological examination 278
 Radiotherapy 012, 067, 068, 076, 165, 403, 434, 537, 538, 588
 Randomised trial 109, 477
 Rare forms 082
 Reactive T-lymphocytes 309
 REAL classification 006, 116, 263, 342
 REAL vs. UN-REAL 042
 Recombinant adeno-associated virus 146
 Reduced combined modality treatment 401
 Reed-Sternberg cells 375, 382
 Refractory aggressive lymphoma 656
 Refractory Hodgkin's disease 179, 669, 670
 Refractory lymphoma 545, 597
 Refractory lymphoproliferative disorders 695
 Refractory non-Hodgkin's lymphoma 655
 Registro Veneto Linfomi, the 266
 Registry based analysis 397
 Regression 476
 Relapse 174, 175, 325, 330, 427, 587, 590
 Relapsed aggressive lymphoma 656
 Relapsed Hodgkin's disease 669, 670
 Relapsed large cell lymphoma 625
 Relapsed low-grade lymphoma 194
 Relapsed lymphoma 545, 600, 601
 Relapsed non-Hodgkin's lymphoma 195, 591, 655
 Remission 380, 519
 Remission rate 593
 Repeated PBSC support 636
 Reproductive potential 182
 Residual cells 324
 Residual disease 324
 Residual mass 112
 Resistant Hodgkin's disease 430
 Resistant lymphoma 600, 601
 Resistant non-Hodgkin's lymphoma 332, 591
 Restin 291
 Restriction fragment 523
 Retrospective analysis 474, 648

Retrospective evaluation 537
 Reverse transcriptase PCR 483
 rG-CSF *see* Filgrastim
 rhG-CSF treatment 641
 rhGM-CSF 599
 rIL2 663
 Risk 026
 Risk-adapted chemotherapy 248
 Risk factors 427, 680
 RT-PCR 303
 Russia 443

S

S phase fraction 154
 S-CA 125 187
 Salvage chemotherapy 054, 055, 590, 592, 598, 630
 Sardinia 262
 sCD23 234
 sCD54 234
 Schistosomiasis 379
 Scotland and Newcastle Lymphoma Group 475
 Second cancers 058, 071, 432, 433
 Second malignant neoplasm 441
 Second neoplasm 444
 Secondary breast lymphoma 460
 Secondary central nervous system lymphoma 454
 Secondary cutaneous B-cell lymphoma 489
 Selective chemotherapy 045
 Semen 516
 Sequelae 435
 Sequence analysis 130
 Sequential chemotherapy 169
 Sequential molecular studies 226
 Sequential therapy 643
 Sero-epidemiological study 254
 Serum CA-125 524
 Serum marker 318
 Sézary Syndrome 121, 484, 492
 SFOP HM 91 protocol 094
 Short G-CSF *see* Neupogen®
 Single cell RT-PCR 019
 Single Hodgkin/Reed-Sternberg cells 019
 Sjogren syndrome 447
 Skin 041
 Small non-cleaved cell lymphomas (SNCL) 017, 261
 South Vietnam 263
 Southern analysis 305
 Southwest Oncology Group 006
 Spleen 270, 338
 Splenic lymphoma 464
 Splenomegaly 156
 Spontaneous apoptosis 310
 SSCP analysis 304
 Stage I large cell lymphoma 568
 Stage I patients 188
 Stage I₀ follicular lymphoma 534
 Stage IE 470
 Stage IE patients 188

Stage II/IV Hodgkin's disease 070
 Stage II large cell lymphoma 568
 Stage IIE 470
 Stage III 391
 Stage III patients 185
 Stage IV Hodgkin's disease 418
 Stage IV patients 185
 Staging classification 465, 467
 Staging laparotomy 067
 Staging patients 111
 Stem cell 627
 Stem cell disorder 300
 Stem cell mobilisation 437
 Stem cell rescue 645
 Stem cell support 244
 Stomach 81, 221
 Subtotal nodal irradiation 400
 Subtype 88
 Success 440, 443
 Surgery 354
 Survival 394
 Survival analysis 393
 Survivors 181
 Sustained complete remission 174
 Sweden 268
 Symptomatic multiple myeloma 698
 Systematic follow-up 533
 Systemic non-Hodgkin lymphoma 050

T

T cell fraction 153
 t(14;18) 128, 294, 325 *see also* Bcl-2 translocation
 t(14;18)(q32;q21) 335
 t(2; 5)(p23;q35) translocation 123, 124, 385, 483
 t(8;13)(p12;q12) 300
 t(8;14)(q24;q32) 015
 t(9;22)(q34;q11) 295
 t(X;18)(q13;p11) 296
 T-cell acute lymphoblastic leukaemia 253
 T-cell cytotoxicity 059
 T-cell derived cytokines 139
 T-cell immunoblastic lymphoma 620
 T-cell lymphoma 030, 099, 346
 T-cell malignant lymphomas 315
 T-cell mediated immunity 061
 T-cell receptor 292
 T helper 2 cytokines 121
 T-lymphotropic retroviral genome 281, 282
 Taxol® *see* Paclitaxel
 TCL1 gene 138
 TdT-positive cells 144
 Testicular lymphoma 455, 456
 Thallium-201 271
 Therapeutic evaluation 390
 Therapeutic options 032
 Thiotepa 655, 674
 Thymus 345
 Thyroid dysfunction 258

Thyroid lymphoma 457, 458
 TNF *see also* Tumour necrosis factor
 TNF-alpha 231
 Tolerance 207
 Total body irradiation 535, 536
 Toxicity 100, 584
 Tracheo-oesophageal fistula 438
 Transformed lymphoma 374
 Transgenic mice 023, 156
 Transrearrangements 026
 Treatment 009, 010, 181a
 Treatment modalities 600
 Trends 027
 Trisomy 12 052
 Trisomy 3 125
 Tumoral dissemination 152
 Tumour 277
 Tumour cells 064
 Tumour lysis syndrome 679
 Tumour necrosis factor (TNF) 301, 330, 686
 Tumour progression 374
 Tumour score 565
 Tumour suppressor genes 134, 323
 Turkey 370
 Turkish study 254

U

UK Children's Cancer Study Group 099
 UKCCSG protocol 570
 Ultrasound guided fine-needle biopsy 270
 Unpurged PBPC transplantation 628
 USA 050

V

v6 isoforms 384
 VACOP-B 248
 VACOPB trial 578
 VACPE 202
 VAD regimen
 Vancouver experience, the 198
 Vanishing bile duct syndrome 446
 VBM 404
 VEBEP 180
 VEMP regimen 651
 Venezuela 520
 Very old patients 698
 VICOPB trial 578
 Villous lymphocytes 464
 Vinblastine 168, 171, 423, 616
 Vincristine 199, 202
 Vindesine 207
 Vinorelbine 597, 598
 VIP regimen 177
 Virus 311
 Virus-associated haemoproliferative disorder 681
 Vitamin D 620
 VNCOP-B treatment 611

VP16 587, 596, 599, 615

W

Wait and See policy 534

Waldenstrom's macroglobulinaemia 690

Waldeyer's ring, the 217

Watch and Wait policy 188

Whole blood derived stem cells 625

Y

Young survivors 071

Yttrium-90 195

Z

ZB-0 cell line 286

ZB-2 cell line 286

Zidovudine (AZT) 617